Adam J Gehring

List of Publications by Year
in descending order

59 papers	5,408 citations	126901 33 h-index	155644 55 g-index
62 all docs	62 docs citations	62 times ranked	7670 citing authors

#	Article	IF	Citations
1	Human Tissues Contain CD141hi Cross-Presenting Dendritic Cells with Functional Homology to Mouse CD103+ Nonlymphoid Dendritic Cells. Immunity, 2012, 37, 60-73.	14.3	643
2	The immune response during hepatitis B virus infection. Journal of General Virology, 2006, 87, 1439-1449.	2.9	343
3	A global scientific strategy to cure hepatitis B. The Lancet Gastroenterology and Hepatology, 2019, 4, 545-558.	8.1	342
4	IL-7 Licenses Activation of Human Liver Intrasinusoidal Mucosal-Associated Invariant T Cells. Journal of Immunology, 2013, 190, 3142-3152.	0.8	298
5	Mycobacterium tuberculosisLprG (Rv1411c): A Novel TLR-2 Ligand That Inhibits Human Macrophage Class II MHC Antigen Processing. Journal of Immunology, 2004, 173, 2660-2668.	0.8	231
6	Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. Journal of Hepatology, 2010, 52, 370-379.	3.7	227
7	Modulation of the CD8⁺-T-Cell Response by CD4⁺CD25⁺Regulatory T Cells in Patients with Hepatitis B Virus Infection. Journal of Virology, 2005, 79, 3322-3328.	3.4	212
8	Toll-Like Receptor 8 Agonist and Bacteria Trigger Potent Activation of Innate Immune Cells in Human Liver. PLoS Pathogens, 2014, 10, e1004210.	4.7	204
9	Mycobacterium tuberculosis LprA Is a Lipoprotein Agonist of TLR2 That Regulates Innate Immunity and APC Function. Journal of Immunology, 2006, 177, 422-429.	0.8	203
10	Bim-mediated deletion of antigen-specific CD8+ T cells in patients unable to control HBV infection. Journal of Clinical Investigation, 2008, 118, 1835-1845.	8.2	187
11	Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. Journal of Hepatology, 2011, 55, 103-110.	3.7	183
12	Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. Lancet Respiratory Medicine,the, 2021, 9, 498-510.	10.7	180
13	Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. Journal of Hepatology, 2015, 62, 486-491.	3.7	160
14	The role of innate immunity in the immunopathology and treatment of HBV infection. Journal of Hepatology, 2016, 64, S60-S70.	3.7	150
15	The Mycobacterium tuberculosis 19-Kilodalton Lipoprotein Inhibits Gamma Interferon-Regulated HLA-DR and Fcî³R1 on Human Macrophages through Toll-Like Receptor 2. Infection and Immunity, 2003, 71, 4487-4497.	2.2	146
16	A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. Journal of Hepatology, 2010, 52, 330-339.	3.7	141
17	Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection. Gastroenterology, 2019, 156, 325-337.	1.3	140
18	Human immunity to M. tuberculosis: T cell subsets and antigen processing. Tuberculosis, 2003, 83, 98-106.	1.9	137

#	Article	IF	Citations
19	Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome. Science Immunology, 2017, 2, .	11.9	135
20	Host Ethnicity and Virus Genotype Shape the Hepatitis B Virus-Specific T-Cell Repertoire. Journal of Virology, 2008, 82, 10986-10997.	3.4	114
21	Engineering T Cells Specific for a Dominant Severe Acute Respiratory Syndrome Coronavirus CD8 T Cell Epitope. Journal of Virology, 2011, 85, 10464-10471.	3.4	86
22	The Level of Viral Antigen Presented by Hepatocytes Influences CD8 T-Cell Function. Journal of Virology, 2007, 81, 2940-2949.	3.4	80
23	Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. Journal of Clinical Investigation, 2013, 123, 3766-3776.	8.2	80
24	Getting to HBV cure: The promising paths forward. Hepatology, 2022, 76, 233-250.	7.3	70
25	A Whole Recombinant Yeast-Based Therapeutic Vaccine Elicits HBV X, S and Core Specific T Cells in Mice and Activates Human T Cells Recognizing Epitopes Linked to Viral Clearance. PLoS ONE, 2014, 9, e101904.	2.5	64
26	Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries. Nature Genetics, 2022, 54, 1103-1116.	21.4	54
27	Immune Therapeutic Strategies in Chronic Hepatitis B Virus Infection: Virus or Inflammation Control?. PLoS Pathogens, 2013, 9, e1003784.	4.7	51
28	Conditional ligands for <scp>A</scp>sian <scp>HLA</scp> variants facilitate the definition of <scp>CD</scp>8⁺<scp>T</scp>â€cell responses in acute and chronic viral diseases. European Journal of Immunology, 2013, 43, 1109-1120.	2.9	49
29	Targeting Hepatitis B Virus-Infected Cells with a T-Cell Receptor-Like Antibody. Journal of Virology, 2011, 85, 1935-1942.	3.4	48
30	T-cell hybridomas from HLA-transgenic mice as tools for analysis of human antigen processing. Journal of Immunological Methods, 2003, 281, 129-142.	1.4	41
31	Mechanisms of HBV immune evasion. Antiviral Research, 2020, 179, 104816.	4.1	40
32	Therapeutic vaccination and novel strategies to treat chronic HBV infection. Expert Review of Gastroenterology and Hepatology, 2009, 3, 561-569.	3.0	38
33	Dissecting the dendritic cell controversy in chronic hepatitis B virus infection. Cellular and Molecular Immunology, 2015, 12, 283-291.	10.5	38
34	HBV-Specific Adaptive Immunity. Viruses, 2009, 1, 91-103.	3.3	33
35	Phosphatidylinositol Mannoside fromMycobacterium tuberculosisBinds Î±5Î²1 Integrin (VLA-5) on CD4+ T Cells and Induces Adhesion to Fibronectin. Journal of Immunology, 2006, 177, 2959-2968.	0.8	32
36	Building and Optimizing a Virus-specific T Cell Receptor Library for Targeted Immunotherapy in Viral Infections. Scientific Reports, 2014, 4, 4166.	3.3	25

#	Article	IF	Citations
37	New treatments to reach functional cure: Rationale and challenges for emerging immune-based therapies. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2017, 31, 337-345.	2.4	21
38	Challenges With Stopping Long-term Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B. Gastroenterology, 2020, 158, 1185-1190.	1.3	18
39	Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection. Frontiers in Immunology, 2021, 12, 648420.	4.8	18
40	Immunological biomarker discovery in cure regimens for chronic hepatitis B virus infection. Journal of Hepatology, 2022, 77, 525-538.	3.7	16
41	Host Factor-Targeted Hepatitis B Virus Therapies. Intervirology, 2014, 57, 158-162.	2.8	15
42	Licensing Virus-Specific T Cells to Secrete the Neutrophil Attracting Chemokine CXCL-8 during Hepatitis B Virus Infection. PLoS ONE, 2011, 6, e23330.	2.5	15
43	RNA Interference Therapy for Chronic Hepatitis B Predicts the Importance of Addressing Viral Integration When Developing Novel Cure Strategies. Viruses, 2021, 13, 581.	3.3	13
44	Hepatitis B virus-specific CD4 T cell responses differentiate functional cure from chronic surface antigen+ infection. Journal of Hepatology, 2022, 77, 1276-1286.	3.7	12
45	How further suppression of virus replication could improve current HBV treatment. Expert Review of Anti-Infective Therapy, 2013, 11, 755-757.	4.4	11
46	Optimized ex vivo stimulation identifies multi-functional HBV-specific T cells in a majority of chronic hepatitis B patients. Scientific Reports, 2020, 10, 11344.	3.3	10
47	Stability Screening of Arrays of Major Histocompatibility Complexes on Combinatorially Encoded Flow Cytometry Beads. Journal of Biological Chemistry, 2011, 286, 28466-28475.	3.4	9
48	The Inflammatory Cytokine Profile Associated With Liver Damage Is Broader and Stronger in Patients With Chronic Hepatitis B Compared to Patients With Acute Hepatitis B. Journal of Infectious Diseases, 2022, 225, 470-475.	4.0	8
49	Immunomodulation and RNA interference alter hepatitis B virusâ€“specific CD8 Tâ€cell recognition of infected HepG2â€NTCP. Hepatology, 2022, 75, 1539-1550.	7.3	7
50	IFN-Î± Suppresses Myeloid Cytokine Production, Impairing IL-12 Production and the Ability to Support T-Cell Proliferation. Journal of Infectious Diseases, 2020, 222, 148-157.	4.0	6
51	Effects of onâ€treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection. Journal of Viral Hepatitis, 2021, 28, 1729-1737.	2.0	6
52	Nucleic Acid Polymer Therapy for Hepatitis B Virus: Strong Hepatitis B Surface Antigen Decline But Many Unanswered Questions. Gastroenterology, 2021, 160, 966-967.	1.3	4
53	Reply to: â€œTo target or not to target viral antigens in HBV related HCC?â€• Journal of Hepatology, 2015, 62, 1450-1452.	3.7	3
54	Binding of TCR Multimers and a TCR-Like Antibody with Distinct Fine-Specificities Is Dependent on the Surface Density of HLA Complexes. PLoS ONE, 2012, 7, e51397.	2.5	2

#	Article	IF	Citations
55	Hostâ€“pathogen interactions in chronic HBV infection and transplantation of HCV-positive organs. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 77-78.	17.8	2
56	Reply. Gastroenterology, 2020, 159, 1187-1188.	1.3	0
57	Immunopathogenesis of Hepatitis B Virus Infection. , 2021, , 73-97.		0
58	The Human Male Liver Is Predisposed to Inflammation Via Enhanced Myeloid Responses to Inflammatory Triggers. Frontiers in Immunology, 2022, 13, 818612.	4.8	0
59	Using Immunomodulatory and Antiviral Strategies in the Quest to Cure Hepatitis B Virus Infection.. Gastroenterology and Hepatology, 2022, 18, 162-165.	0.1	0